The global Frontotemporal Dementia Management Market is expected to garner a market value of USD 10 Million in 2023 and is expected to accumulate a market value of USD 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Frontotemporal Dementia Management registered a CAGR of 4% in the historical period 2018 to 2022.
According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth. Although the cause of Frontotemporal dementia is still unknown it majorly affects individuals between the ages of 40 to 60. Frontotemporal dementia causes serious psychotic episodes and language and communication problems not limited to patients only but affects people around them.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 10 Million |
| Anticipated Forecast Value (2033) | USD 17.91 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Frontotemporal Dementia Management reflected a value of 4% during the historical period, 2018 to 2022.
A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering effective ways for Frontotemporal Dementia Management.
The market's growth is also attributed to the factors such as growing disease prevalence, a rise in lifestyle-associated concerns, and technological advancements. Furthermore, the increasing incidence of dementia patients, increasing research and development investments, and increasing drug development grants and funding by the government, as well as non-government organizations, are propelling immense growth.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for Frontotemporal Dementia Management. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of dementia and others is fuelling the market growth. Thus, the market for Frontotemporal Dementia Management is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Increased Prevalence of the Condition to Push the Market Growth
The high prevalence of dementia is driving the growth of the market owing to treatment advancements and the development of novel therapies for dementia. Furthermore, the vulnerable aging population, government incentives, and benefits through special designation. According to the Centers for Disease Control and Prevention, by 2060, the number of Alzheimer’s disease cases is predicted to rise to an estimated 14 million people, with minority populations being affected the most.
Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting drug development as the patient base of Frontotemporal dementia is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal dementia management.
These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop dementia. The population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Frontotemporal Dementia Management, less awareness of the condition, lack of proper diagnosis and higher chances of misunderstanding Alzheimer’s disease, and insubstantial and poor treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.
Improvement in healthcare spending propelling the growth of Frontotemporal Dementia Management in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Frontotemporal Dementia Management Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.
China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.
The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to the increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.
Technological Advancements Shaping Landscape for Frontotemporal Dementia Management in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. According to the Centers for Disease Control and Prevention, current estimates are that about 5.8 million people in the USA have Alzheimer’s disease and related dementias, including 5.6 million aged 65 and older and about 200,000 under age 65 with younger-onset Alzheimer’s.
Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under the auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the U.S.A Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.
Government initiatives, an increase in the number of research partnerships, the presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool are boosting the market growth across North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Antidepressants as an effective treatment to drive the market
A study conducted by the National Center for Biotechnology Information included ten studies with a total of 1592 patients. Eight included studies reported sufficiently detailed results to enter into analyses related to antidepressant efficacy. To analyze, the organization had nine groups of patients with dementia treated with antidepressants compared with nine groups receiving placebo treatment. As a result, participants on antidepressants were probably more likely to drop out of treatment than those on placebo over 6 to 13 weeks.
Considering this, FMI concludes that there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.
Hospital Pharmacies to take the lead and drive market growth
According to the FMI analysis, Hospital pharmacies account for the largest market share. The requirement for several hospital stays and visits during Frontotemporal Dementia Management facilitates the growth of this segment. The majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
Key start-ups in the market include-
Key players in the Frontotemporal Dementia Management Market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 10 Million |
| Market Value in 2033 | USD 17.91 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class Type, Distribution Channel, End-User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | United States of America, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, Association of Southeast Asian Nations, Gulf Cooperation Council, South Africa, |
| Key Companies Profiled | Pfizer Inc.; Johnson & Johnson; Sanofi S.A.; Eli Lilly and Company; GlaxoSmithKline Plc.; Novartis AG; Mylan N.V.; Merck & Company, Inc.; AstraZeneca plc.; Allergen plc |
| Customization | Available Upon Request |
The market is valued at USD 10.1 million in 2023.
Pfizer Inc., Johnson & Johnson, and Sanofi S.A. are the vital market players.
The market is predicted to be worth USD 17.9 million by 2033.
The high prevalence of dementia is likely to drive the market prospects.
Asia Pacific is likely to generate 5.0% revenue through 2033.
1. Executive Summary | Frontotemporal Dementia Management Market
2. Market Overview
3. Market Background
4. Global analysis 2018 to 2022 and Forecast, 2023 to 2033
5. Global analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class Type
5.1. Antidepressants
5.1.1. Fluoxetine
5.1.2. Fluvoxamine
5.1.3. Sertraline
5.1.4. Paroxetine
5.1.5. Citalopram
5.1.6. Bupropion
5.1.7. Mirtazapine
5.2. Antipsychotics
5.2.1. Olanzapine
5.2.2. Quetiapine
5.2.3. Ziprasidone
5.2.4. Aripiprazole
5.2.5. Risperidone
5.2.6. Paliperidone
6. Global analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Hospital Pharmacy
6.2. Retail Pharmacy
6.3. Drug Store
6.4. Online Pharmacy
6.5. Others
7. Global analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Hospitals
7.2. Specialty Clinics
7.3. Others
8. Global analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. North America
8.2. Latin America
8.3. Europe
8.4. Asia Pacific
8.5. Middle East and Africa (MEA)
9. North America analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10. Latin America analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11. Europe analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12. Asia Pacific analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13. MEA analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14. Key Country's analysis
15. Market Structure Analysis
16. Competition Analysis
16.1. Pfizer Inc.
16.2. Novartis AG
16.3. F. Hoffmann-La Roche Ltd.
16.4. AstraZeneca GmbH
16.5. Sanofi S.A
16.6. Merck & Co., Inc.
16.7. TauRx Pharmaceuticals
16.8. Alector Pharma Co.
16.9. Bausch Health Companies Inc.
16.10. GlaxoSmithKline Plc.
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Frontotemporal Dementia Management Market
